By David Cassak
October 16th, 2003, is a warm, sunny day in Houston, what passes for autumn in South Texas, and from his...
Seven years ago, Cyberonics was all but dead, with an interesting technology and little else. Left at the altar when St. Jude refused to exercise an option to buy the company, Cyberonics faced the daunting task of getting FDA approval for a novel approach to epilepsy therapy and convincing a conservative customer group, neurologists, of the value of its vagus nerve stimuation (VNS) therapy. But Cyberonics was able to establish VNS in epilepsy and the company is now targeting depression, a market that could be as much as ten times larger than its first indication. And as Cyberonics' prospects brighten, the company now faces the challenge of keeping would-be acquirers at bay.
By David Cassak
October 16th, 2003, is a warm, sunny day in Houston, what passes for autumn in South Texas, and from his...
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.